Analysis of Financial Track Record
Value Creation |
|---|
| Mar'10 | Mar'11 | Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Capital Employed | 11.28% | 9.28% | 10.05% | 8.17% | 7.27% | 3.4% | -10.32% | -36.37% | -226.55% | 29.24% |
| Growth Parameters |
|---|
| 9 yrs | 5 yrs | 3 yrs | 1 yr | |
|---|---|---|---|---|
| Net Sales | -17.3% | -30.8% | -39.9% | 39.7% |
| Adjusted EPS | -194.6% | -217.6% | NA | NA |
| Book Value per Share | -206 | -206.2 | -239.2 | 0 |
| Share Price | -13.1% | -20% | 14.3% | 32.8% |
| Key Financial Parameter |
|---|
Management X-Ray
Shareholding Pattern
| Entity | Percentage Holding |
|---|---|
| Promoters | 8.36% |
| Non-Institutions | 91.64% |
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
FAQs
The 5-year analysis of Sanjivani Paranteral's performance infers:
Sanjivani Paranteral earnings have declined by -217.6%, whereas share price has depreciated -20% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.We analysed the performance of Sanjivani Paranteral share prices over the last 10 years. Here is what we found out:
Sanjivani Paranteral share price has depreciated -17.1% annually over the past ten years. About Company
Sanjivani Parenteral was established in 1997 by A H Khemka, Ashwin Khemka and Somesh Khemka, under the technical direction of Mahendra Kalwankar. It is a research-based, international pharmaceutical company that provides a wide range of high quality products and services at affordable prices. The core product range of the company’s products includes oral solids, small volume parenterals and sterile powder formulations.
The company has grown many folds and aspires to be a respected
Sanjivani Parenteral was established in 1997 by A H Khemka, Ashwin Khemka and Somesh Khemka, under the technical direction of Mahendra Kalwankar. It is a research-based, international pharmaceutical company that provides a wide range of high quality products and services at affordable prices. The core product range of the company’s products includes oral solids, small volume parenterals and sterile powder formulations.
The company has grown many folds and aspires to be a respected research-based company. With its diverse product portfolio, it is rapidly expanding its reach to the global marketplace, riding on its success in India and in the world’s emerging and developed markets.
After establishing itself in India, Sanjivani has extended its reach globally by entering the markets of Asia, Europe, Africa and Latin America. The company has active presence in countries like Russia, Ukraine, Uzbekistan, Turkmenistan, Fiji, Vietnam, Sri Lanka, Nepal, Malaysia, Thailand, Nigeria and Peru, to name a few. Sanjivani Parenteral has also got its plant approved by the registration authorities of Congo, Sudan and Sri Lanka. It is making its presence felt in the world market now, through leveraging its manufacturing capacity, quality of products and international alliances.
International business contributes about 30% of the company’s revenue and is set to grow to more than 50% in the coming two years. This includes the sales of Sanjivani’s own brands and the revenue from the contract manufacturing services that the company provides to its overseas clients. The company is in the making of a strong base to broaden its horizons.
Sanjivani has been a regular supplier to the armed forces’ hospitals in India. Furthermore, many government and private hospitals have availed of the products and services offered by Sanjivani across the country. The company also has its own marketing operations in India and boasts of over 1000 distributors all over India.
Products
- Therapeutic Products
- Animal Products
- Key Products
- Oral Solids
